Rheumatoid arthritis combined with bronchiectasis:analysis of clinical features and associated risk factors

Yong LIU,Yong-chang SUN,Xiao-fang LIU

DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2013.018.007

2013-01-01

Abstract:Objective To investigate the clinical characteristics and risk factors of rheumatoid arthritis combined with bronchiectasis (RA-BR) by retrospective analysis of cases.Methods The clinical data of cases diagnosed as RA-BR were compared with those of cases with RA only in Beiing Tongren Hospital from May 2008 to May 2013.A logistic regression analysis was performed to investigate the independent risk factors.Results Sixty-six cases diagnosed as RA were analyzed including 19 cases of RA-BR and 47 cases of RA only.Respiratory manifestation was found in eight cases (8/19,42.1％) of RA-BR patients with RA duration (16.6±9.1) years and respiratory duration (4.6± 11.7) years.RA proceeding BR was found in 14 cases (14/19,73.7 ％) and the mean duration was about 12 years.BR was mostly located in the right middle lobe and right lower lobe (52.6％ and 36.8％).Compared with RA group,RA duration (P =0.045),PEF (P =0.000),FEV1.0 (P =0.032),FEF25-75 (P =0.002) and DLCO (P =0.008) were found significant difference in RA-BR group.There was no difference in lab tests between RA-BR and RA group,such as RF,APF,CCP,ANA,SSA,SSB,ESR,and CRP.No difference was found in disease-modifying treatment and corticosteroid usage between these two groups,too.Multivariate analysis showed that RA duration (P =0.018) and using leflunomide (P =0.026) were independent risk factors.Conclusions Bronchiectasis is not unusual in RA patients.The predominant BR distribution is right middle lobe and right lower lobe.The abnormal PFT results are usually found in RA-BR cases including obstructive respiratory dysfunction,small airway dysfunction,and diffusion dysfunction.RA duration and using leflunomide are the independent risk factors.